Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. (Q37899888)

25 August 2017

1 reference

title

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. (English)

1 reference

25 August 2017

0 references

2

Nadia Harbeck

0 references

Eva Johanna Kantelhardt

10

object named as

Eva J Kantelhardt

1 reference

25 August 2017

Manfred Schmitt

1

1 reference

25 August 2017

Nils Brünner

3

1 reference

25 August 2017

Fritz Jänicke

4

1 reference

25 August 2017

Christoph Meisner

5

1 reference

25 August 2017

Bernd Mühlenweg

6

1 reference

25 August 2017

Heike Jansen

7

1 reference

25 August 2017

Julia Dorn

8

1 reference

25 August 2017

Ulrike Nitz

9

1 reference

25 August 2017

Christoph Thomssen

11

1 reference

25 August 2017

1 July 2011

1 reference

Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare

25 August 2017

1 reference

25 August 2017

11

1 reference

25 August 2017

6

1 reference

25 August 2017

617-634

1 reference

Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects

25 August 2017

1 reference

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

21 January 2018

1 reference

Protease degradomics: a new challenge for proteomics

21 January 2018

1 reference

Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

21 January 2018

1 reference

The urokinase plasminogen activator system: a target for anti-cancer therapy.

21 January 2018

1 reference

Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms

21 January 2018

1 reference

Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer

21 January 2018

1 reference

Personalized treatment of early-stage breast cancer: present concepts and future directions

21 January 2018

1 reference

Gene expression profiling of breast cancer: a new tumor marker

21 January 2018

1 reference

Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays

21 January 2018

1 reference

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

21 January 2018

1 reference

National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers

21 January 2018

1 reference

Adjuvant chemotherapy for primary breast cancer

21 January 2018

1 reference

Facts and controversies in systemic treatment of metastatic breast cancer

21 January 2018

1 reference

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

21 January 2018

1 reference

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

21 January 2018

1 reference

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

21 January 2018

1 reference

UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers.

21 January 2018

1 reference

Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001.

21 January 2018

1 reference

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

21 January 2018

1 reference

Adjuvant docetaxel for high-risk, node-negative breast cancer

21 January 2018

1 reference

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

21 January 2018

1 reference

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

21 January 2018

1 reference

Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours

21 January 2018

1 reference

Re-engineering of human urokinase provides a system for structure-based drug design at high resolution and reveals a novel structural subsite

21 January 2018

1 reference

Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties

21 January 2018

1 reference

Small, potent, and selective diaryl phosphonate inhibitors for urokinase-type plasminogen activator with in vivo antimetastatic properties

21 January 2018

1 reference

Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer

21 January 2018

1 reference

A urokinase-derived peptide (A6) increases survival of mice bearing orthotopically grown prostate cancer and reduces lymph node metastasis

21 January 2018

1 reference

A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin

21 January 2018

1 reference

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial

21 January 2018

1 reference

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

21 January 2018

1 reference

A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes

21 January 2018

1 reference

Inhibition of choroidal neovascularization in rats by the urokinase-derived peptide A6.

21 January 2018

1 reference

Effect of a novel octapeptide urokinase fragment, A6, on experimental choroidal neovascularization in the monkey

21 January 2018

1 reference

Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer

21 January 2018

1 reference

Optimizing chemotherapy regimens for patients with early-stage breast cancer

21 January 2018

1 reference

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

21 January 2018

1 reference

RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.

21 January 2018

1 reference

PAI-1 - a potential therapeutic target in cancer

21 January 2018

1 reference

The molecular pathology of cancer

21 January 2018

1 reference

Gene-expression signatures in breast cancer

21 January 2018

1 reference

ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors

21 January 2018

1 reference

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

21 January 2018

1 reference

REporting recommendations for tumor MARKer prognostic studies (REMARK).

21 January 2018

1 reference

A new look at node-negative breast cancer.

21 January 2018

1 reference

Anti-cancer therapies targeting the tumor stroma

21 January 2018

1 reference

The plasmin-antiplasmin system: structural and functional aspects

21 January 2018

1 reference

New insights into the molecular mechanisms of the fibrinolytic system

21 January 2018

1 reference

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel

21 January 2018

1 reference

National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers

21 January 2018

1 reference

Age dependence of ischaemic heart syndromes and the contribution of haemostatic deviations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERM.11.47

1 reference

25 August 2017

1 reference